SCHEMBL30925530

SCHEMBL30925530

Cc1cccnc1S(=O)(=O)Nc1cccc2ncc(N3CCC3)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 10/20 0.52
▸ ALOX15 P16050 3/20 0.42
▸ HTT P42858 3/20 0.42
▸ NPSR1 Q6W5P4 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ S1PR4 O95977 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ S1PR1 P21453 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TDP1 Q9NUW8 3/20 0.39
▸ OPRK1 P41145 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ TLR9 Q9NR96 1/20 0.39
▸ CLK1 P49759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214297 0.91 MET (0.49) METALOX15HTTNPSR1LMNA
SCHEMBL30925479 0.91 MET (0.49) METALOX15HTTNPSR1LMNA
SCHEMBL27214195 0.75 SLC40A1 (0.47) ALOX15HTTNPSR1LMNAMEN1
SCHEMBL30925573 0.75 SLC40A1 (0.47) ALOX15HTTNPSR1LMNAMEN1
SCHEMBL30925400 0.73 SLC40A1 (0.51) ALOX15HTTNPSR1LMNAMEN1
SCHEMBL30925585 0.68 ALDH1A1 (0.40) ALOX15HTTNPSR1LMNATP53
SCHEMBL30925535 0.68 SLC40A1 (0.73) ALOX15HTTNPSR1LMNAMEN1
SCHEMBL27214328 0.68 SLC40A1 (0.73) ALOX15HTTNPSR1LMNAMEN1
SCHEMBL30553464 0.68 KMO (0.43) ALOX15HTTNPSR1LMNAMEN1
SCHEMBL26964398 0.68 KMO (0.43) ALOX15HTTNPSR1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 MET 3930/4885ALOX15 2472/4885HTT 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback